Liu P, Olivieri N
Centre for Cardiovascular Research, Toronto Hospital, Canada.
Cardiovasc Drugs Ther. 1994 Feb;8(1):101-10. doi: 10.1007/BF00877096.
Iron overload cardiomyopathy is an old disease that has evolved from a rare undiagnosable and untreatable condition to a now much more common, diagnosable, and potentially treatable condition. Pathologically it is due to a direct free iron effect on the myocytes, and not due to interstitial infiltration. This also implies that the disease process is reversible if the tissue iron concentration can be controlled. The advent of magnetic resonance imaging and future genetic identification can identify the population at risk. Chelation therapy, including newer forms of oral chelators, likely will be more commonly available to benefit an ever increasing number and spectrum of the population. Further active research will be needed to improve our pathophysiological understanding and clinical treatment of this increasingly common condition.
铁过载心肌病是一种古老的疾病，它已从一种罕见的无法诊断和治疗的病症演变为一种现在更为常见、可诊断且有潜在治疗方法的病症。从病理学角度来看，它是由于游离铁对心肌细胞的直接作用，而非间质浸润所致。这也意味着，如果组织铁浓度能够得到控制，疾病进程是可逆的。磁共振成像技术的出现以及未来的基因鉴定能够识别出高危人群。螯合疗法，包括新型口服螯合剂，可能会越来越普遍地用于使越来越多不同类型的人群受益。需要进一步积极开展研究，以增进我们对这种日益常见病症的病理生理学理解和临床治疗水平。
